NewsBenzingaReported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients Benzinga 2026.10.05 06:57 (GMT+0) Open on Benzinga Other news The Biggest Winners from the Anthropic IPO Could Be Everyday SPY Investors Bitdeer (BTDR) Stock Falls 15.21% Intraday, Now at $2.89 Bausch + Lomb Corporation (BLCO) Discusses Phase II Results for BL1332 in Ocular Surface Pain Transcript Wells Fargo Maintains Overweight on California Resources, Raises Price Target to $77 B. Riley Securities Reiterates Buy on Orchestra BioMed Hldgs, Raises Price Target to $12 PerpetualCow: $13 Million XMR Theft Traced to Compromise of Hosting Provider 1984
Bausch + Lomb Corporation (BLCO) Discusses Phase II Results for BL1332 in Ocular Surface Pain Transcript